Thanh Huynh Neville

Thanh Huynh Neville

Auto-generated profile, based on publicly available information

Thanh Huynh Neville

Department of Medicine, Division of Pulmonary Critical Care, University of California, Los Angeles, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2003 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
CSCharlotte J. Sumner
Charlotte J. Sumner
THThanh N. Huynh
Thanh N. Huynh
JMJennifer A. Markowitz
Jennifer A. Markowitz
JPJ. Stephen Perhac
J. Stephen Perhac
BHBrenna Hill
Brenna Hill
KFKenneth H. Fischbeck
Kenneth H. Fischbeck

11 November 2013 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
THThanh N. Huynh
Thanh N. Huynh
EKEric C. Kleerup
Eric C. Kleerup
JWJoshua F. Wiley
Joshua F. Wiley
TSTerrance D. Savitsky
Terrance D. Savitsky
DGDiana Guse
Diana Guse
NWNeil S. Wenger
Neil S. Wenger
Advances in medicine enable critical care specialists to save lives as well as prolong dying. An admission to the intensive care unit (ICU) should be considered a therapeutic trial—aggressive critical care should transition to palliative care once it is clear that the treatment will not achieve an acceptable health state for the patient.1,2 However, intensive care interventions often sustain life under circumstances that will not achieve an outcome that patients can meaningfully appreciate. Such treatments are often perceived to be “futile” by health care providers.3 A survey of ICU physicians in Canada found that as many as 87% believed that futile treatment had been provided in their ICU in the past year.3 In a single-day cross-sectional study performed in Europe, 27% of ICU clinicians believed that they provided “inappropriate” care to at least 1 patient, and most of the inappropriate care was deemed such because it was excessive.4

16 March 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
LKLauren E. Kernochan
Lauren E. Kernochan
MRMelissa L. Russo
Melissa L. Russo
NWNathaniel S. Woodling
Nathaniel S. Woodling
THThanh N. Huynh
Thanh N. Huynh
AAAmy M. Avila
Amy M. Avila
CSCharlotte J. Sumner
Charlotte J. Sumner
Increasing survival motor neuron 2 (SMN2) gene expression may be an effective strategy for the treatment of spinal muscular atrophy (SMA). Histone deacetylase (HDAC) inhibitors have been shown to increase SMN transcript and protein levels, but the specific role of histone acetylation in regulating SMN gene expression has not been explored. Using chromatin immunopreciptation, we investigated the levels of acetylated H3 and H4 histones and HDACs associated with different regions of the human and mouse SMN genes in both cultured cells and tissues. We show that the SMN gene has a reproducible pattern of histone acetylation that is largely conserved among different tissues and species. A limited region of the promoter surrounding the transcriptional start site has relatively high levels of histone acetylation, whereas regions further upstream or downstream have lower levels. After HDAC inhibitor treatment, acetylated histone levels increased, particularly at upstream regions, correlating with a 2-fold increase in promoter activity. During development in mouse tissues, histone acetylation levels decreased and associated HDAC2 levels increased at the region closest to the transcriptional start site, correlating with a 40–60% decrease in SMN transcript and protein levels. These data indicate that histone acetylation modulates SMN gene expression and that pharmacological manipulation of this epigenetic determinant is feasible. HDAC2, in particular, may be a future therapeutic target for SMA.

1 February 2024 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
JKJacqueline M. Kruser
Jacqueline M. Kruser
DADeepshikha C. Ashana
Deepshikha C. Ashana
KCKatherine R. Courtright
Katherine R. Courtright
EKErin K. Kross
Erin K. Kross
TNThanh H. Neville
Thanh H. Neville
CCChristopher E. Cox
Christopher E. Cox
In critical care, the specific, structured approach to patient care known as a “time-limited trial” has been promoted in the literature to help patients, surrogate decision makers, and clinicians navigate consequential decisions about life-sustaining therapy in the face of uncertainty. Despite promotion of the time-limited trial approach, a lack of consensus about its definition and essential elements prevents optimal clinical use and rigorous evaluation of its impact. The objectives of this American Thoracic Society Workshop Committee were to establish a consensus definition of a time-limited trial in critical care, identify the essential elements for conducting a time-limited trial, and prioritize directions for future work. We achieved these objectives through a structured search of the literature, a modified Delphi process with 100 interdisciplinary and interprofessional stakeholders, and iterative committee discussions. We conclude that a time-limited trial for patients with critical illness is a collaborative plan among clinicians and a patient and/or their surrogate decision makers to use life-sustaining therapy for a defined duration, after which the patient’s response to therapy informs the decision to continue care directed toward recovery, transition to care focused exclusively on comfort, or extend the trial’s duration. The plan’s 16 essential elements follow four sequential phases: consider, plan, support, and reassess. We acknowledge considerable gaps in evidence about the impact of time-limited trials and highlight a concern that if inadequately implemented, time-limited trials may perpetuate unintended harm. Future work is needed to better implement this defined, specific approach to care in practice through a person-centered equity lens and to evaluate its impact on patients, surrogates, and clinicians.

1 September 2014 in Critical Care Medicine
Verified
Journal Article
Closed access
THThanh N. Md Huynh
Thanh N. Md Huynh
EKEric C. Kleerup
Eric C. Kleerup
PRPrince P. Mha Raj
Prince P. Mha Raj
NWNeil S. Wenger
Neil S. Wenger
Objective: When used to prolong life without achieving a benefit meaningful to the patient, critical care is often considered “futile.” Although futile treatment is acknowledged as a misuse of resources by many, no study has evaluated its opportunity cost, that is, how it affects care for others. Our objective was to evaluate delays in care when futile treatment is provided. Design: For 3 months, we surveyed critical care physicians in five ICUs to identify patients that clinicians identified as receiving futile treatment. We identified days when an ICU was full and contained at least one patient who was receiving futile treatment. For those days, we evaluated the number of patients waiting for ICU admission more than 4 hours in the emergency department or more than 1 day at an outside hospital. Setting: One health system that included a quaternary care medical center and an affiliated community hospital. Patients: Critically ill patients. Interventions: None. Measurements and Main Results: Boarding time in the emergency department and waiting time on the transfer list. Thirty-six critical care specialists made 6,916 assessments on 1,136 patients of whom 123 were assessed to receive futile treatment. A full ICU was less likely to contain a patient receiving futile treatment compared with an ICU with available beds (38% vs 68%, p < 0.001). On 72 (16%) days, an ICU was full and contained at least one patient receiving futile treatment. During these days, 33 patients boarded in the emergency department for more than 4 hours after admitted to the ICU team, nine patients waited more than 1 day to be transferred from an outside hospital, and 15 patients canceled the transfer request after waiting more than 1 day. Two patients died while waiting to be transferred. Conclusions: Futile critical care was associated with delays in care to other patients.

1 November 2013 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
THThanh N. Huynh
Thanh N. Huynh
AWAnne M. Walling
Anne M. Walling
TLThuy X. Le
Thuy X. Le
EKEric C. Kleerup
Eric C. Kleerup
HLHonghu Liu
Honghu Liu
NWNeil S. Wenger
Neil S. Wenger
Background: In imminently dying patients, mechanical ventilation withdrawal is often a comfort measure and avoids prolonging the dying process. Objective: The aim of the study was to identify factors associated with palliative withdrawal of mechanical ventilation and time to death after extubation. Methods: Logistic regression models were used to identify factors associated with palliative withdrawal of mechanical ventilation. Cox proportional hazards models were used to determine factors associated with time to death after extubation. We retrospectively evaluated 322 patients who died on mechanical ventilation or after palliative ventilator withdrawal at a single tertiary care center. Results: Of the 322 ventilated deaths, 159 patients had palliative withdrawal of mechanical ventilation and 163 patients died on the ventilator. Clinical service was associated with palliative withdrawal of mechanical ventilation: Patients withdrawn from the ventilator were less likely to be on the surgery service and more likely to be on the neurology/neurosurgical service. The median time to death was 0.9 hours (range 0–165 hours). Fraction of inspired oxygen (FIO2) greater than 70% (hazard ratio [HR] 1.92, 95% confidence interval [CI ]1.24–2.99) and a requirement for vasopressors (HR 2.06, 95% CI 1.38–3.09) were associated with shorter time to death. Being on the neurology/neurosurgical service at the time of ventilator withdrawal was associated with a longer time to death (HR 0.60, 95% CI 0.39–0.92). Conclusions: Palliative withdrawal of mechanical ventilation was performed in only half of dying mechanically ventilated patients. Because clinical service rather than physiologic parameters are associated with withdrawal, targeted interventions may improve withdrawal decisions. Considering FIO2 and vasopressor requirements may facilitate counseling families about anticipated time to death.